miR-107 inhibited malignant biological behavior of non-small cell lung cancer cells by regulating the STK33/ERK signaling pathway
Non-small cell lung cancer (NSCLC)
STK33/ERK signaling pathway
cell apoptosis
cell invasion
cell proliferation
miR-107
tumor growth
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
ppublish
Résumé
The role of miRNAs in non-small cell lung cancer (NSCLC) has been broadly studied and confirmed, and miR-107 has attracted an ever-growing level of attention. This study set out to research the mechanism of the effect of miR-107 on the malignant biological behavior of NSCLC The expression of miRNAs related to the development of NSCLC was detected by RT-qPCR. Western blotting was carried out to detect expression levels of serine/threonine kinase 33 (STK33) and proteins related to the extracellular regulated protein kinases (ERK) signaling pathway, while cell proliferation was detected using cell counting kit-8 (CCK-8). The cell apoptosis rate was measured using flow cytometry. The invasion ability was detected by Transwell assay. In vivo tumor growth assays were performed on mice. The expression ERK signaling pathway-related proteins In NSCLC cell lines and tissues, miR-107 was downregulated. Overexpression of miR-107 inhibited malignant biological behavior of NSCLC cell lines, and suppressed tumor growth miR-107 inhibited malignant biological behavior of NSCLC through regulation of the STK33/ERK signaling pathway.
Sections du résumé
BACKGROUND
BACKGROUND
The role of miRNAs in non-small cell lung cancer (NSCLC) has been broadly studied and confirmed, and miR-107 has attracted an ever-growing level of attention. This study set out to research the mechanism of the effect of miR-107 on the malignant biological behavior of NSCLC
METHODS
METHODS
The expression of miRNAs related to the development of NSCLC was detected by RT-qPCR. Western blotting was carried out to detect expression levels of serine/threonine kinase 33 (STK33) and proteins related to the extracellular regulated protein kinases (ERK) signaling pathway, while cell proliferation was detected using cell counting kit-8 (CCK-8). The cell apoptosis rate was measured using flow cytometry. The invasion ability was detected by Transwell assay. In vivo tumor growth assays were performed on mice. The expression ERK signaling pathway-related proteins
RESULTS
RESULTS
In NSCLC cell lines and tissues, miR-107 was downregulated. Overexpression of miR-107 inhibited malignant biological behavior of NSCLC cell lines, and suppressed tumor growth
CONCLUSIONS
CONCLUSIONS
miR-107 inhibited malignant biological behavior of NSCLC through regulation of the STK33/ERK signaling pathway.
Identifiants
pubmed: 32395291
doi: 10.21037/jtd.2020.03.103
pii: jtd-12-04-1540
pmc: PMC7212150
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1540-1551Informations de copyright
2020 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd.2020.03.103). The authors have no conflicts of interest to declare.
Références
Biosci Rep. 2019 Mar 1;39(3):
pubmed: 30760631
Onco Targets Ther. 2019 Jul 26;12:6033-6043
pubmed: 31440060
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4545-51
pubmed: 25120851
Int J Clin Exp Pathol. 2014 Sep 15;7(10):7236-41
pubmed: 25400821
Int J Oncol. 2016 Oct;49(4):1325-33
pubmed: 27498977
Neoplasma. 2019 Sep;66(5):704-716
pubmed: 31129966
Neuroendocrinology. 2020;110(3-4):307-320
pubmed: 31261148
Cell. 2009 May 29;137(5):821-34
pubmed: 19490892
Aging (Albany NY). 2019 Sep 8;11(17):6734-6761
pubmed: 31498117
Curr Mol Med. 2020;20(2):90-101
pubmed: 31573883
Cell Mol Life Sci. 2015 Aug;72(16):3127-41
pubmed: 26037721
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Oncol Lett. 2017 Oct;14(4):4800-4804
pubmed: 29085482
Appl Immunohistochem Mol Morphol. 2019 Jul 30;:
pubmed: 31394555
Neoplasma. 2017;64(6):869-879
pubmed: 28895411
Biochem Biophys Res Commun. 2019 Apr 30;512(2):331-337
pubmed: 30885433
Front Genet. 2019 Sep 10;10:809
pubmed: 31552102
Clin Cancer Res. 2017 Sep 1;23(17):5311-5319
pubmed: 28606918
Ann Transl Med. 2018 Dec;6(23):446
pubmed: 30603634
Oncol Lett. 2018 Feb;15(2):2153-2160
pubmed: 29434919
Am J Cancer Res. 2017 Sep 01;7(9):1863-1873
pubmed: 28979809
Eur J Cancer. 2018 Aug;99:20-27
pubmed: 29894909
PLoS One. 2009 Aug 18;4(8):e6677
pubmed: 19688090
Gene. 2017 Jul 15;620:46-53
pubmed: 28392366
Sci Rep. 2016 Nov 09;6:36531
pubmed: 27827403
BMC Cancer. 2019 Aug 22;19(1):829
pubmed: 31438892
Cancer Res. 2017 Dec 15;77(24):6851-6862
pubmed: 29038348